Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

CBST 69.03 +0.12 (0.17%)
price chart
Cubist Pharmaceuticals: Ripe For Acquisition?
Large-cap pharmaceutical companies that can easily benefit from the acquisition include Pfizer Inc. (PFE), which could absorb Cubist's sales force into its acute-care division. Eli Lilly and Co (LLY) and Johnson & Johnson (JNJ) could also come to the ...
Cubist Pharmaceuticals COO Sells $63871 in Stock (CBST)  Mideast Time
Cubist Battling Superbugs Offers Remedy for J&J: Real M&A  Businessweek
Related articles »  
Cubist Recalls Its Lifesaving Drug Cubicin
Cubist Pharmaceuticals Inc (CBST) announced yesterday, it is recalling 101 production lots of its antibiotic Cubicin (daptomycin injection) amid fear of glass particles being present in the drug.
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of ...  MarketWatch
Cubist Pharma Recalls Some Vials of Antibiotic Cubicin  Medscape
Related articles »  
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review
The European Medicines Agency (EMA) accepted Cubist Pharmaceuticals, Inc.'s (CBST - Analyst Report) Marketing Authorization Application (MAA) for its investigational antibiotic, ceftolozane/tazobactam.
Cubist to Present New Data from Antibiotics Portfolio at 54 th Interscience ...  Business Wire (press release)
Related articles »  
Biotech Equities Roundup -- Keryx Biopharma, Vertex Pharma, NPS Pharma ...
Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. KERX, +1.62% Vertex Pharmaceuticals Inc. VRTX, -0.65% NPS Pharmaceuticals Inc. NPSP, +3.13% Cubist Pharmaceuticals Inc. CBST, -0.41% and Idera ...
Related articles »  
Cubist Pharmaceuticals SVP Gregory Stea Unloads 38326 Shares (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) SVP Gregory Stea unloaded 38,326 shares of the company's stock on the open market in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $65.88, ...
Cubist Pharmaceuticals Director Nancy J. Hutson Sells 9000 Shares (CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported $0.23 earnings per share for the quarter, beating the analysts' consensus estimate of $0.01 by $0.22.
Cubist Pharmaceuticals Rating Lowered to Underperform at Zacks (CBST)  Ticker Report
Related articles »  
Active Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lumos Networks ...
Cubist Pharmaceuticals (NASDAQ:CBST) has been given an average rating of �Buy� by the fourteen brokerages that are currently covering the company. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy ...
Best Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Electronics for ...
FDA is reporting that Cubist Pharmaceuticals Inc. (NASDAQ:CBST) on 8 August has announced it is voluntarily recalling certain lots of CUBICIN (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in ...
Cubist Pharmaceuticals Receives Average Rating of �Buy� from Brokerages ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has been given an average rating of �Buy� by the fourteen brokerages that are currently covering the company, Stock Ratings reports. Four research analysts have rated the ...
Related articles »  
Worth Watching Stocks: Cubist Pharmaceuticals (NASDAQ:CBST), Geron ...
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced that it will present new data at the 54thInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington, D.C.